The National Institutes of Health (NIH) announced projects selected to receive 2012 Bridging Interventional Development Gaps (BrIDGs) support. BrIDGs, formerly known as NIH Rapid Access to Interventional Development, is supported by the NIH Common Fund. Rather than funding successful applicants directly, BrIDGs enables NIH contractors to provide pre-clinical services and facilitates the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.
As announced by the NIH, BrIDGs selected the following new projects from its 2012 application solicitation:
Tumor Penetrating Microparticles for Peritoneal Cancers
Jessie Au, PharMD, PhD, chief scientific officer and acting chief executive officer
Optimum Therapeutics, LLC, San Diego
This project focuses on cancers that affect organs in the peritoneal cavity such as the bladder, liver and pancreas. A drug delivery system, called tumor-penetrating microparticles, is under development to target peritoneal tumors.
Lecithin-cholesterol acyltransferase (LCAT) deficiency syndrome
Development of Assays to Detect Anti-drug Antibodies against ACP-501 (recombinant human LCAT)
Brian Krause, PhD, chief scientific officer
Alphacore Pharma, LLC, Ann Arbor, Mich.
Lecithin-cholesterol acyltransferase deficiency syndrome is a rare disorder that causes a drastic reduction of high-density lipoprotein (HDL) cholesterol levels in patients. This leads to disorders of the cornea (the transparent lens on the eye), anemia, and may cause kidney failure. The objective of this project is to develop a treatment called recombinant human LCAT that would act as a replacement therapy to offset the deficiency caused by LCAT deficiency syndrome.
Spinal Cord Injury
Development of Nogo Receptor Decoy for the Treatment of Spinal Cord Injury
George Maynard, PhD, vice president, Preclinical Development
Axerion Therapeutics, Inc., New Haven, Conn.
Recovery after a spinal cord injury is limited, as nerve cell growth is virtually nonexistent in the adult spinal cord. This project aims to develop a compound called Nogo Receptor Decoy to …